NEW YORK, April 11 (GenomeWeb News) - Invitrogen and Signalomics of Germany will collaborate to develop nanocrystal reagents for cancer diagnostics, Invitrogen said today.
Initially, the partners want to develop an imaging agent that can be used to identify colon carcinomas that require surgery.
Signalomics, based in Steinfurt, has been developing in vivo diagnostics based on designer proteins coupled to fluorescent semiconductor crystals. The proteins target faulty signaling proteins that are expressed in tumor tissues. In the body, they can be visualized by a laser light that makes the crystal-protein conjugates emit light in different colors.
The agreement allows Signalomics to continue its collaboration with BioPixels, which Invitrogen acquired in October. Signalomics has been working with BioPixels, a former business unit of BioCrystal, since 2004.